New Clinical Guidelines Reclassify Stuttering as a Brain-Based Disorder

The guidelines, developed by a 35-member international panel, represent the first interdisciplinary effort to standardize care for an estimated 80 million people worldwide. By categorizing stuttering as a neuropsychiatric condition, the panel highlights critical links to neurodevelopmental disorders like ADHD, OCD, and autism. This shift in perspective aims to move clinical practice away from superficial fluency-based assessments toward a holistic model that addresses social, emotional, and occupational well-being.

A central focus of the report is the pharmacological management of the condition. The panel warns that stimulants used for ADHD, along with bupropion and certain Parkinson’s treatments, may exacerbate symptoms by increasing dopamine activity. Instead, they point toward dopamine antagonists or partial agonists, such as aripiprazole, as having the strongest current evidence for clinical use. Despite these insights, nearly 90 percent of the expert panel rated the current treatment landscape as poor, citing a chronic shortage of trained providers and a lack of standardized diagnostic biomarkers.

To bridge these gaps, the society advocates for a coordinated diagnostic approach that includes screening for comorbidities and autoimmune factors. The guidelines mandate that physicians, pediatricians, and speech-language pathologists work in concert rather than in silos. Moving forward, STARS plans to expand educational resources for schools and employers, pushing for a standardized framework that treats the disorder with the same medical rigor historically applied to conditions like Tourette syndrome.